CVAC DEMONSTRATES OVERALL SURVIVAL BENEFIT IN

0.0250 (0.00%)View full PRR report with
  1. 1.8k
    Posts

    CVAC DEMONSTRATES OVERALL SURVIVAL BENEFIT

    IN SECOND REMISSION OVARIAN CANCER :shock :cool: :cool:

    Well done this is fantastic news basically Ovarian cancer patients living longer already a great step forward.

    Great news.

    Overall Survival data from the CAN-003 trial continues to show benefit for second

    remission ovarian cancer patients (second remission patients) using CVac

    Half of standard of care second remission patients survived past 25.53 months; more

    than half of CVac treated patients still alive after 36 months

    Data to be included in Poster presentation at SITC Annual Conference

Your browser is too old for TopStocks and not secure. Please update your browser